> top > docs > PubMed:20103725 > annotations

PubMed:20103725 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T2 0-16 O62725 denotes Cyclooxygenase-2
T3 0-16 Q05769 denotes Cyclooxygenase-2
T4 0-16 P35355 denotes Cyclooxygenase-2
T5 0-16 P79208 denotes Cyclooxygenase-2
T6 0-16 P35354 denotes Cyclooxygenase-2
T7 0-16 O02768 denotes Cyclooxygenase-2
T8 0-16 PR:000013428 denotes Cyclooxygenase-2
T9 0-16 P27607 denotes Cyclooxygenase-2
T10 0-16 O19183 denotes Cyclooxygenase-2
T11 0-16 O62698 denotes Cyclooxygenase-2
T12 0-16 P70682 denotes Cyclooxygenase-2
T13 0-16 D051546 denotes Cyclooxygenase-2
T14 77-83 UBERON:0000310 denotes breast
T15 77-90 D001943 denotes breast cancer
T16 77-90 D001943 denotes breast cancer
T17 94-101 CVCL_J973 denotes a her-2
T18 96-101 PR:P04626 denotes her-2
T19 96-101 PR:000002082 denotes her-2
T20 96-101 PR:Q03557 denotes her-2
T21 96-101 PR:P34708 denotes her-2
T22 96-101 PR:Q5AK64 denotes her-2
T23 102-105 PR:P04626 denotes neu
T24 102-105 PR:000002082 denotes neu
T25 102-105 PR:000011145 denotes neu
T26 102-105 PR:P70424 denotes neu
T28 102-105 PR:000011149 denotes neu
T29 102-105 PR:O35657 denotes neu
T30 102-105 PR:P06494 denotes neu
T31 102-105 PR:P29503 denotes neu
T27 102-105 CHEBI:23995 denotes neu
T32 106-111 10090 denotes mouse
T33 106-111 D051379 denotes mouse
T36 126-143 D002278 denotes carcinoma in situ
T37 126-143 D002278 denotes carcinoma in situ
T39 145-149 CVCL_5552 denotes DCIS
T38 145-149 D002285 denotes DCIS
T40 145-149 D002285 denotes DCIS
T41 190-196 UBERON:0000310 denotes breast
T42 190-203 D001943 denotes breast cancer
T43 190-203 D001943 denotes breast cancer
T45 259-263 CVCL_5552 denotes DCIS
T44 259-263 D002285 denotes DCIS
T46 259-263 D002285 denotes DCIS
T48 277-293 O62725 denotes cyclooxygenase 2
T49 277-293 Q05769 denotes cyclooxygenase 2
T50 277-293 P35355 denotes cyclooxygenase 2
T51 277-293 P79208 denotes cyclooxygenase 2
T52 277-293 P35354 denotes cyclooxygenase 2
T53 277-293 O02768 denotes cyclooxygenase 2
T54 277-293 PR:000013428 denotes cyclooxygenase 2
T55 277-293 P27607 denotes cyclooxygenase 2
T56 277-293 O19183 denotes cyclooxygenase 2
T57 277-293 O62698 denotes cyclooxygenase 2
T58 277-293 P70682 denotes cyclooxygenase 2
T59 277-293 D051546 denotes cyclooxygenase 2
T65 295-298 CVCL_E534 denotes COX
T68 295-300 PR:Q9MIY7 denotes COX-2
T69 295-300 P35354 denotes COX-2
T70 295-300 P27607 denotes COX-2
T71 295-300 PR:O62698 denotes COX-2
T72 295-300 PR:000025365 denotes COX-2
T73 295-300 P79208 denotes COX-2
T74 295-300 PR:P21534 denotes COX-2
T75 295-300 O19183 denotes COX-2
T76 295-300 P70682 denotes COX-2
T77 295-300 PR:P00410 denotes COX-2
T78 295-300 PR:P00406 denotes COX-2
T79 295-300 O62725 denotes COX-2
T80 295-300 P35355 denotes COX-2
T81 295-300 PR:P35354 denotes COX-2
T82 295-300 PR:000013428 denotes COX-2
T83 295-300 O62698 denotes COX-2
T84 295-300 PR:P00403 denotes COX-2
T85 295-300 Q05769 denotes COX-2
T86 295-300 PR:P24894 denotes COX-2
T87 295-300 PR:P00405 denotes COX-2
T88 295-300 O02768 denotes COX-2
T89 295-300 PR:P93285 denotes COX-2
T90 295-300 PR:Q05769 denotes COX-2
T91 295-300 PR:P35355 denotes COX-2
T92 295-300 PR:P79208 denotes COX-2
T94 349-353 CVCL_5552 denotes DCIS
T93 349-353 D002285 denotes DCIS
T95 349-353 D002285 denotes DCIS
T96 361-370 140587 denotes Celecoxib
T97 361-370 D000068579 denotes Celecoxib
T98 361-370 D000068579 denotes Celecoxib
T99 361-370 CHEBI:41423 denotes Celecoxib
T100 389-411 CHEBI:35472 denotes anti-inflammatory drug
T107 438-441 CVCL_E534 denotes COX
T110 438-443 PR:Q9MIY7 denotes COX-2
T111 438-443 P35354 denotes COX-2
T112 438-443 P27607 denotes COX-2
T113 438-443 PR:O62698 denotes COX-2
T114 438-443 PR:000025365 denotes COX-2
T115 438-443 P79208 denotes COX-2
T116 438-443 PR:P21534 denotes COX-2
T117 438-443 O19183 denotes COX-2
T118 438-443 P70682 denotes COX-2
T119 438-443 PR:P00410 denotes COX-2
T120 438-443 PR:P00406 denotes COX-2
T121 438-443 O62725 denotes COX-2
T122 438-443 P35355 denotes COX-2
T123 438-443 PR:P35354 denotes COX-2
T124 438-443 PR:000013428 denotes COX-2
T125 438-443 O62698 denotes COX-2
T126 438-443 PR:P00403 denotes COX-2
T127 438-443 Q05769 denotes COX-2
T128 438-443 PR:P24894 denotes COX-2
T129 438-443 PR:P00405 denotes COX-2
T130 438-443 O02768 denotes COX-2
T131 438-443 PR:P93285 denotes COX-2
T132 438-443 PR:Q05769 denotes COX-2
T133 438-443 PR:P35355 denotes COX-2
T134 438-443 PR:P79208 denotes COX-2
T140 481-484 CVCL_E534 denotes COX
T143 481-486 PR:Q9MIY7 denotes COX-2
T144 481-486 P35354 denotes COX-2
T145 481-486 P27607 denotes COX-2
T146 481-486 PR:O62698 denotes COX-2
T147 481-486 PR:000025365 denotes COX-2
T148 481-486 P79208 denotes COX-2
T149 481-486 PR:P21534 denotes COX-2
T150 481-486 O19183 denotes COX-2
T151 481-486 P70682 denotes COX-2
T152 481-486 PR:P00410 denotes COX-2
T153 481-486 PR:P00406 denotes COX-2
T154 481-486 O62725 denotes COX-2
T155 481-486 P35355 denotes COX-2
T156 481-486 PR:P35354 denotes COX-2
T157 481-486 PR:000013428 denotes COX-2
T158 481-486 O62698 denotes COX-2
T159 481-486 PR:P00403 denotes COX-2
T160 481-486 Q05769 denotes COX-2
T161 481-486 PR:P24894 denotes COX-2
T162 481-486 PR:P00405 denotes COX-2
T163 481-486 O02768 denotes COX-2
T164 481-486 PR:P93285 denotes COX-2
T165 481-486 PR:Q05769 denotes COX-2
T166 481-486 PR:P35355 denotes COX-2
T167 481-486 PR:P79208 denotes COX-2
T168 501-510 140587 denotes celecoxib
T169 501-510 D000068579 denotes celecoxib
T170 501-510 D000068579 denotes celecoxib
T171 501-510 CHEBI:41423 denotes celecoxib
T172 551-557 UBERON:0000310 denotes breast
T173 551-564 D001943 denotes breast cancer
T174 551-564 D001943 denotes breast cancer
T175 597-603 UBERON:0000310 denotes breast
T176 597-610 D001943 denotes breast cancer
T177 597-610 D001943 denotes breast cancer
T178 614-621 MGI:87853 denotes a mouse
T179 616-621 10090 denotes mouse
T180 616-621 D051379 denotes mouse
T181 659-667 PR:P48775 denotes to human
T182 662-667 D006801 denotes human
T184 682-686 CVCL_5552 denotes DCIS
T183 682-686 D002285 denotes DCIS
T185 682-686 D002285 denotes DCIS
T186 705-710 10090 denotes mouse
T187 705-710 D051379 denotes mouse
T192 717-748 11757 denotes mouse mammary tumor virus (MMTV
T193 731-736 D009369 denotes tumor
T194 731-736 D009369 denotes tumor
T197 750-753 PR:P04626 denotes Neu
T198 750-753 PR:000002082 denotes Neu
T199 750-753 PR:000011145 denotes Neu
T200 750-753 PR:P70424 denotes Neu
T202 750-753 PR:000011149 denotes Neu
T203 750-753 PR:O35657 denotes Neu
T204 750-753 PR:P06494 denotes Neu
T205 750-753 PR:P29503 denotes Neu
T201 750-753 CHEBI:23995 denotes Neu
T206 793-797 PR:000005054 denotes mice
T208 793-797 O89094 denotes mice
T207 793-797 D051379 denotes mice
T209 793-797 10095 denotes mice
T211 806-809 PR:P63003-1 denotes rat
T212 806-809 PR:Q2G0B1 denotes rat
T213 806-809 PR:Q8VHJ4 denotes rat
T210 806-809 10116 denotes rat
T214 806-809 D051381 denotes rat
T215 810-815 PR:P04626 denotes Her-2
T216 810-815 PR:000002082 denotes Her-2
T217 810-815 PR:Q03557 denotes Her-2
T218 810-815 PR:P34708 denotes Her-2
T219 810-815 PR:Q5AK64 denotes Her-2
T220 816-819 PR:P04626 denotes Neu
T221 816-819 PR:000002082 denotes Neu
T222 816-819 PR:000011145 denotes Neu
T223 816-819 PR:P70424 denotes Neu
T225 816-819 PR:000011149 denotes Neu
T226 816-819 PR:O35657 denotes Neu
T227 816-819 PR:P06494 denotes Neu
T228 816-819 PR:P29503 denotes Neu
T224 816-819 CHEBI:23995 denotes Neu
T229 820-829 SO:0000902 denotes transgene
T231 855-859 CVCL_5552 denotes DCIS
T230 855-859 D002285 denotes DCIS
T232 855-859 D002285 denotes DCIS
T233 898-907 140587 denotes celecoxib
T234 898-907 D000068579 denotes celecoxib
T235 898-907 D000068579 denotes celecoxib
T236 898-907 CHEBI:41423 denotes celecoxib
T237 913-916 Q6I7B6 denotes ppm
T238 967-972 D009369 denotes tumor
T239 967-972 D009369 denotes tumor
T240 995-1000 D009369 denotes tumor
T241 995-1000 D009369 denotes tumor
T242 1036-1040 PR:000005054 denotes mice
T244 1036-1040 O89094 denotes mice
T243 1036-1040 D051379 denotes mice
T245 1036-1040 10095 denotes mice
T246 1064-1068 CHEBI:23888 denotes drug
T247 1088-1101 D063646 denotes tumorigenesis
T248 1088-1101 D063646 denotes tumorigenesis
T249 1164-1170 D009369 denotes tumors
T250 1164-1170 D009369 denotes tumors
T251 1183-1187 UBERON:0002048 denotes lung
T252 1188-1198 D009362 denotes metastasis
T253 1188-1198 D009362 denotes metastasis
T254 1213-1226 CHEBI:26333 denotes prostaglandin
T255 1268-1274 D009369 denotes tumors
T256 1268-1274 D009369 denotes tumors
T257 1286-1290 PR:000005054 denotes mice
T259 1286-1290 O89094 denotes mice
T258 1286-1290 D051379 denotes mice
T260 1286-1290 10095 denotes mice
T261 1305-1314 140587 denotes celecoxib
T262 1305-1314 D000068579 denotes celecoxib
T263 1305-1314 D000068579 denotes celecoxib
T264 1305-1314 CHEBI:41423 denotes celecoxib
T265 1347-1356 GO:0097194 denotes apoptosis
T266 1347-1356 GO:0006915 denotes apoptosis
T267 1371-1405 D042461 denotes vascular endothelial growth factor
T269 1371-1405 D042461 denotes vascular endothelial growth factor
T268 1371-1405 GO:0005172 denotes vascular endothelial growth factor
T272 1392-1405 P08441 denotes growth factor
T273 1392-1405 P08072 denotes growth factor
T274 1392-1405 Q776B5 denotes growth factor
T275 1392-1405 Q6RZT5 denotes growth factor
T276 1392-1405 Q8V307 denotes growth factor
T282 1554-1557 CVCL_E534 denotes COX
T285 1554-1559 PR:Q9MIY7 denotes COX-2
T286 1554-1559 P35354 denotes COX-2
T287 1554-1559 P27607 denotes COX-2
T288 1554-1559 PR:O62698 denotes COX-2
T289 1554-1559 PR:000025365 denotes COX-2
T290 1554-1559 P79208 denotes COX-2
T291 1554-1559 PR:P21534 denotes COX-2
T292 1554-1559 O19183 denotes COX-2
T293 1554-1559 P70682 denotes COX-2
T294 1554-1559 PR:P00410 denotes COX-2
T295 1554-1559 PR:P00406 denotes COX-2
T296 1554-1559 O62725 denotes COX-2
T297 1554-1559 P35355 denotes COX-2
T298 1554-1559 PR:P35354 denotes COX-2
T299 1554-1559 PR:000013428 denotes COX-2
T300 1554-1559 O62698 denotes COX-2
T301 1554-1559 PR:P00403 denotes COX-2
T302 1554-1559 Q05769 denotes COX-2
T303 1554-1559 PR:P24894 denotes COX-2
T304 1554-1559 PR:P00405 denotes COX-2
T305 1554-1559 O02768 denotes COX-2
T306 1554-1559 PR:P93285 denotes COX-2
T307 1554-1559 PR:Q05769 denotes COX-2
T308 1554-1559 PR:P35355 denotes COX-2
T309 1554-1559 PR:P79208 denotes COX-2
T310 1564-1570 UBERON:0000310 denotes breast
T311 1564-1577 D001943 denotes breast cancer
T312 1564-1577 D001943 denotes breast cancer

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-118 Sentence denotes Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
T2 119-204 Sentence denotes Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer.
T3 205-264 Sentence denotes Several molecular alterations have been identified in DCIS.
T4 265-360 Sentence denotes Among them, cyclooxygenase 2 (COX-2) overexpression has been shown in 60% to 80% of DCIS cases.
T5 361-444 Sentence denotes Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2.
T6 445-687 Sentence denotes In this study, we evaluated whether COX-2 inhibition by celecoxib can reduce the incidence of preinvasive breast cancer and its progression to invasive breast cancer in a mouse model exhibiting a similar phenotype to human solid-pattern DCIS.
T7 688-786 Sentence denotes We have used the mouse model mouse mammary tumor virus (MMTV)-Neu to investigate this possibility.
T8 787-873 Sentence denotes These mice carry a rat Her-2/Neu transgene and are known to develop DCIS-like lesions.
T9 874-1041 Sentence denotes Our results showed that celecoxib (500 ppm) given as prophylaxis was neither able to prevent tumor development nor delay tumor appearance compared with untreated mice.
T10 1042-1199 Sentence denotes Furthermore, when the drug was given early in tumorigenesis, it did not reduce the progression of preinvasive to invasive tumors nor prevent lung metastasis.
T11 1200-1291 Sentence denotes Reduction of prostaglandin levels was, however, achieved in mammary tumors of treated mice.
T12 1292-1436 Sentence denotes In addition, celecoxib treatment caused an increase in apoptosis and decreased vascular endothelial growth factor expression in treated animals.
T13 1437-1578 Sentence denotes Our results contrast with some previously published studies and highlight the complexity of the relationship between COX-2 and breast cancer.
T1 0-118 Sentence denotes Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
T2 119-204 Sentence denotes Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer.
T3 205-264 Sentence denotes Several molecular alterations have been identified in DCIS.
T4 265-360 Sentence denotes Among them, cyclooxygenase 2 (COX-2) overexpression has been shown in 60% to 80% of DCIS cases.
T5 361-444 Sentence denotes Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2.
T6 445-687 Sentence denotes In this study, we evaluated whether COX-2 inhibition by celecoxib can reduce the incidence of preinvasive breast cancer and its progression to invasive breast cancer in a mouse model exhibiting a similar phenotype to human solid-pattern DCIS.
T7 688-786 Sentence denotes We have used the mouse model mouse mammary tumor virus (MMTV)-Neu to investigate this possibility.
T8 787-873 Sentence denotes These mice carry a rat Her-2/Neu transgene and are known to develop DCIS-like lesions.
T9 874-1041 Sentence denotes Our results showed that celecoxib (500 ppm) given as prophylaxis was neither able to prevent tumor development nor delay tumor appearance compared with untreated mice.
T10 1042-1199 Sentence denotes Furthermore, when the drug was given early in tumorigenesis, it did not reduce the progression of preinvasive to invasive tumors nor prevent lung metastasis.
T11 1200-1291 Sentence denotes Reduction of prostaglandin levels was, however, achieved in mammary tumors of treated mice.
T12 1292-1436 Sentence denotes In addition, celecoxib treatment caused an increase in apoptosis and decreased vascular endothelial growth factor expression in treated animals.
T13 1437-1578 Sentence denotes Our results contrast with some previously published studies and highlight the complexity of the relationship between COX-2 and breast cancer.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 190-203 HP_0003002 denotes breast cancer
T2 190-203 HP_0100013 denotes breast cancer
T3 197-203 HP_0002664 denotes cancer
T4 551-564 HP_0003002 denotes breast cancer
T5 551-564 HP_0100013 denotes breast cancer
T6 558-564 HP_0002664 denotes cancer
T7 597-610 HP_0003002 denotes breast cancer
T8 597-610 HP_0100013 denotes breast cancer
T9 604-610 HP_0002664 denotes cancer
T10 731-736 HP_0002664 denotes tumor
T11 967-972 HP_0002664 denotes tumor
T12 995-1000 HP_0002664 denotes tumor
T13 1164-1170 HP_0002664 denotes tumors
T14 1268-1274 HP_0002664 denotes tumors
T15 1564-1577 HP_0003002 denotes breast cancer
T16 1564-1577 HP_0100013 denotes breast cancer
T17 1571-1577 HP_0002664 denotes cancer

Allie

Id Subject Object Predicate Lexical cue
SS1_20103725_1_0 119-143 expanded denotes Ductal carcinoma in situ
SS2_20103725_1_0 145-149 abbr denotes DCIS
SS1_20103725_3_0 277-293 expanded denotes cyclooxygenase 2
SS2_20103725_3_0 295-300 abbr denotes COX-2
SS1_20103725_6_0 717-742 expanded denotes mouse mammary tumor virus
SS2_20103725_6_0 744-748 abbr denotes MMTV
AE1_20103725_1_0 SS1_20103725_1_0 SS2_20103725_1_0 abbreviatedTo Ductal carcinoma in situ,DCIS
AE1_20103725_3_0 SS1_20103725_3_0 SS2_20103725_3_0 abbreviatedTo cyclooxygenase 2,COX-2
AE1_20103725_6_0 SS1_20103725_6_0 SS2_20103725_6_0 abbreviatedTo mouse mammary tumor virus,MMTV

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-118 DRI_Background denotes Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
T2 119-204 DRI_Background denotes Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer.
T3 205-264 DRI_Background denotes Several molecular alterations have been identified in DCIS.
T4 265-360 DRI_Background denotes Among them, cyclooxygenase 2 (COX-2) overexpression has been shown in 60% to 80% of DCIS cases.
T5 361-444 DRI_Background denotes Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2.
T6 445-687 DRI_Approach denotes In this study, we evaluated whether COX-2 inhibition by celecoxib can reduce the incidence of preinvasive breast cancer and its progression to invasive breast cancer in a mouse model exhibiting a similar phenotype to human solid-pattern DCIS.
T7 688-786 DRI_Approach denotes We have used the mouse model mouse mammary tumor virus (MMTV)-Neu to investigate this possibility.
T8 787-873 DRI_Background denotes These mice carry a rat Her-2/Neu transgene and are known to develop DCIS-like lesions.
T9 874-1041 DRI_Outcome denotes Our results showed that celecoxib (500 ppm) given as prophylaxis was neither able to prevent tumor development nor delay tumor appearance compared with untreated mice.
T10 1042-1199 DRI_Challenge denotes Furthermore, when the drug was given early in tumorigenesis, it did not reduce the progression of preinvasive to invasive tumors nor prevent lung metastasis.
T11 1200-1291 DRI_Background denotes Reduction of prostaglandin levels was, however, achieved in mammary tumors of treated mice.
T12 1292-1436 DRI_Background denotes In addition, celecoxib treatment caused an increase in apoptosis and decreased vascular endothelial growth factor expression in treated animals.
T13 1437-1578 DRI_Outcome denotes Our results contrast with some previously published studies and highlight the complexity of the relationship between COX-2 and breast cancer.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 119-204 DRI_Background denotes Ductal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer.
T2 205-264 DRI_Background denotes Several molecular alterations have been identified in DCIS.
T3 265-360 DRI_Background denotes Among them, cyclooxygenase 2 (COX-2) overexpression has been shown in 60% to 80% of DCIS cases.
T4 361-444 DRI_Background denotes Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2.
T5 445-687 DRI_Approach denotes In this study, we evaluated whether COX-2 inhibition by celecoxib can reduce the incidence of preinvasive breast cancer and its progression to invasive breast cancer in a mouse model exhibiting a similar phenotype to human solid-pattern DCIS.
T6 688-786 DRI_Approach denotes We have used the mouse model mouse mammary tumor virus (MMTV)-Neu to investigate this possibility.
T7 787-873 DRI_Background denotes These mice carry a rat Her-2/Neu transgene and are known to develop DCIS-like lesions.
T8 874-1041 DRI_Outcome denotes Our results showed that celecoxib (500 ppm) given as prophylaxis was neither able to prevent tumor development nor delay tumor appearance compared with untreated mice.
T9 1042-1199 DRI_Challenge denotes Furthermore, when the drug was given early in tumorigenesis, it did not reduce the progression of preinvasive to invasive tumors nor prevent lung metastasis.
T10 1200-1291 DRI_Background denotes Reduction of prostaglandin levels was, however, achieved in mammary tumors of treated mice.
T11 1292-1436 DRI_Background denotes In addition, celecoxib treatment caused an increase in apoptosis and decreased vascular endothelial growth factor expression in treated animals.
T12 1437-1578 DRI_Outcome denotes Our results contrast with some previously published studies and highlight the complexity of the relationship between COX-2 and breast cancer.